SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
NCT00101244 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31
Last updated 2013-01-14
Summary
This phase I trial is studying the side effects and best dose of SB-715992 in treating patients with metastatic or unresectable solid tumors or Hodgkin's or non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
Conditions
- Adult Grade III Lymphomatoid Granulomatosis
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Grade III Lymphomatoid Granulomatosis
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Splenic Marginal Zone Lymphoma
- Stage IV Adult Burkitt Lymphoma
- Stage IV Adult Diffuse Large Cell Lymphoma
- Stage IV Adult Diffuse Mixed Cell Lymphoma
- Stage IV Adult Diffuse Small Cleaved Cell Lymphoma
- Stage IV Adult Hodgkin Lymphoma
- Stage IV Adult Immunoblastic Large Cell Lymphoma
- Stage IV Adult Lymphoblastic Lymphoma
- Stage IV Grade 1 Follicular Lymphoma
- Stage IV Grade 2 Follicular Lymphoma
- Stage IV Grade 3 Follicular Lymphoma
- Stage IV Mantle Cell Lymphoma
- Stage IV Marginal Zone Lymphoma
- Stage IV Small Lymphocytic Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific
- Waldenström Macroglobulinemia
Interventions
- DRUG
-
ispinesib
Given IV
- OTHER
-
laboratory biomarker analysis
Correlative studies
- OTHER
-
pharmacological study
Correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Patricia LoRusso · Barbara Ann Karmanos Cancer Institute
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-11-30
- Primary Completion
- 2010-02-28
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
NCT02561273 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003784 ·Status: COMPLETED ·Phase: PHASE2
-
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
NCT01158274 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
NCT00396864 ·Status: COMPLETED ·Phase: PHASE1
-
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT03128164 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
NCT00695448 ·Status: TERMINATED ·Phase: PHASE1
-
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
NCT06487624 ·Status: RECRUITING ·Phase: PHASE1
-
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
NCT00005964 ·Status: COMPLETED ·Phase: PHASE2
-
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00348985 ·Status: COMPLETED ·Phase: PHASE1
-
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
NCT00499811 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
NCT00854126 ·Status: COMPLETED ·Phase: PHASE1
-
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
NCT00311558 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
NCT04746131 ·Status: SUSPENDED ·Phase: PHASE1
-
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
NCT00243087 ·Status: COMPLETED ·Phase: PHASE1
-
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00323934 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
NCT01703481 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
NCT01258998 ·Status: COMPLETED ·Phase: PHASE2
-
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
NCT02153580 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
NCT02082977 ·Status: TERMINATED ·Phase: PHASE1
-
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
NCT00089089 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00002494 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
NCT00001430 ·Status: COMPLETED ·Phase: PHASE2
-
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
NCT05650580 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
NCT05337735 ·Status: SUSPENDED ·Phase: PHASE2